CAPRICOR THERAPEUTICS

Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio

29 4 2021 07:00:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

11 3 2021 15:01:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform

09 3 2021 08:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11

04 3 2021 08:00:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines

01 2 2021 08:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes

19 1 2021 08:15:00 提供 Nasdaq GlobeNewswire

Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

12 1 2021 08:05:00 提供 Nasdaq GlobeNewswire